Proteomics International

Proteomics International company information, Employees & Contact Information

Proteomics International Laboratories Limited (ASX:PIQ) is a medical technology company at the forefront of predictive diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease. Proteomics International is now implementing a stepped rollout of PromarkerD, its flagship diagnostic test for diabetic kidney disease, globally. Successful commercialisation of this diagnostic test is expected to bolster Proteomics’ revenue base. PromarkerD licensing fees and royalty payments will rise as the test is adopted by more physicians and licensed into new geographic regions. The Company is, at the same time, continuing to research potential diagnostic tests for other diseases, including endometriosis, asthma, COPD, oesophageal cancer, Diabetic retinopathy and oxidative stress. Proteomics’ Analytical Services unit provides fee-for-service revenue, which helps financially support the Company’s commercialisation and research activities. To learn more please visit: www.proteomics.com.au/
Looking for a particular Proteomics International employee's phone or email?

Proteomics International Questions

News

Proteomics makes blood test breakthrough for deadly throat cancer - The Sydney Morning Herald

Proteomics makes blood test breakthrough for deadly throat cancer The Sydney Morning Herald

Proteomics flags US rollout of kidney test at global diabetes summit - The Sydney Morning Herald

Proteomics flags US rollout of kidney test at global diabetes summit The Sydney Morning Herald

Proteomics scores approval for Perth diagnostics lab - The Sydney Morning Herald

Proteomics scores approval for Perth diagnostics lab The Sydney Morning Herald

Anti-CAMP1 IgG promotes macrophage phagocytosis of Cutibacterium acnes type II - ScienceDirect.com

Anti-CAMP1 IgG promotes macrophage phagocytosis of Cutibacterium acnes type II ScienceDirect.com

ASX health stocks: Proteomics tumbles 22pc on delayed product launch, Race hits 10mth highs - Stockhead

ASX health stocks: Proteomics tumbles 22pc on delayed product launch, Race hits 10mth highs Stockhead

$6M boost to drive industrial-scale Proteomics facility in WA - The Sydney Morning Herald

$6M boost to drive industrial-scale Proteomics facility in WA The Sydney Morning Herald

Proteomics International clinches EU patent for ‘breakthrough’ kidney disease test - smallcaps.com.au

Proteomics International clinches EU patent for ‘breakthrough’ kidney disease test smallcaps.com.au

ASX Health Stocks: Proteomics to start selling in France; Recce to start clinical trials - Stockhead

ASX Health Stocks: Proteomics to start selling in France; Recce to start clinical trials Stockhead

New Proteomics blood test unlocks better oesophageal cancer detection - The Sydney Morning Herald

New Proteomics blood test unlocks better oesophageal cancer detection The Sydney Morning Herald

Proteomics launches predictive kidney disease test in Australia - The Sydney Morning Herald

Proteomics launches predictive kidney disease test in Australia The Sydney Morning Herald

Proteomics nails near perfect results for endometriosis blood test - The Sydney Morning Herald

Proteomics nails near perfect results for endometriosis blood test The Sydney Morning Herald

Proteomics adds biotech stalwart to boost diagnostics growth - The Sydney Morning Herald

Proteomics adds biotech stalwart to boost diagnostics growth The Sydney Morning Herald

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant